The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD)

Plain-language summary

This study examined the role of the JAK2 gene in alveolar macrophage cells in the lungs of people with chronic beryllium disease, using blood draws and bronchoscopy. It enrolled people with a history of beryllium exposure and test-confirmed chronic beryllium disease or beryllium sensitization. It was conducted as a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

National Jewish Health

Intervention

Blood draw, bronchoscopy

Start date

4/1/2015

Estimated completion

12/6/2019

Countries

United States

Related genes

Locations

• Denver, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Chronic Beryllium Disease - These individuals will meet the following inclusion criteria:

Inclusion Criteria:

1. History of beryllium exposure;
2. Positive blood and/or bronchoalveolar lavage (BAL) Beryllium Lymphocyte Proliferation Tests (BeLPT);
3. Biopsy-proven pathologic changes consistent with CBD, specifically non-caseating granulomas and/or mononuclear cell interstitial infiltrates .

Beryllium Sensitization - These individuals will meet the following inclusion criteria:

Inclusion Criteria:

1. History of beryllium exposure;
2. Two or more positive blood beryllium lymphocyte proliferation tests (BeLPT) or positive bronchoalveolar lavage (BAL) BeLPT;
3. Normal lung tissue (no histology suggestive of CBD).

Exclusion Criteria:

\-